Cytek Biosciences
CTKB
160 hedge funds and large institutions have $311M invested in Cytek Biosciences in 2025 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 50 increasing their positions, 65 reducing their positions, and 21 closing their positions.
38% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 21
5% more funds holding
Funds holding: 152 → 160 (+8)
0.54% more ownership
Funds ownership: 59.98% → 60.51% (+0.54%)
23% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 65
38% less capital invested
Capital invested by funds: $501M → $311M (-$191M)
91% less call options, than puts
Call options by funds: $2K | Put options by funds: $22K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Topline Capital Management
Santa Monica,
California
|
+$6.4M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$5.3M |
| 3 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
+$4.38M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$3.67M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$10.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$9.85M |
| 3 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
-$4.06M |
| 4 |
BlackRock
New York
|
-$2.14M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.93M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AAP
176
Arax Advisory Partners
Denver,
Colorado
| – | -$1.21K | -187 | Closed |
|
|
AF
177
Allworth Financial
Folsom,
California
| – | -$566 | -98 | Closed |
|
|
LC
178
Lindbrook Capital
Calabasas,
California
| – | -$610 | -94 | Closed |
|
|
PFBT
179
Parkside Financial Bank & Trust
Saint Louis,
Missouri
| – | -$254 | -39 | Closed |
|
180
Simplex Trading
Chicago,
Illinois
| – | +$679 | +131 | New |
|
CTKB Hedge Fund Activity: Q1 2025 in Review
160 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q1 2025, worth a combined $311M — down 38% from $501M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new CTKB positions and 21 closed out — a net gain of 8 holders — while 50 added to existing stakes and 65 trimmed.
The largest buyer was Topline Capital Management, adding an estimated $6.4M. The largest seller was Vanguard Group, cutting an estimated $10.9M.
- 160 institutional investors held Cytek Biosciences (CTKB) as of Q1 2025, up from 152 in Q4 2024.
- Funds reported $311M of Cytek Biosciences stock for Q1 2025, down 38% quarter-over-quarter.
- 29 funds opened new Cytek Biosciences positions in Q1 2025 and 21 closed out, a net change of +8 holders.
- The largest Cytek Biosciences buyer in Q1 2025 was Topline Capital Management, an estimated $6.4M added.
- The largest Cytek Biosciences seller in Q1 2025 was Vanguard Group, an estimated $10.9M sold.
Based on aggregated 13F filings for Q1 2025.